首页MPSYF • OTCMKTS
add
Morphosys Ord Shs
市场资讯
财务信息
损益表
收入
净收入
(EUR) | 2024年6月info | 年同比变化 |
---|---|---|
收入 | 3464.38万 | -34.84% |
经营支出 | 7893.35万 | -17.78% |
净收入 | -7919.31万 | -7.07% |
净利润率 | -228.59 | -64.30% |
每股收益 | — | — |
息税折旧摊销前利润 | -4437.82万 | 6.70% |
有效税率 | — | — |
资产负债表
总资产
负债总额
(EUR) | 2024年6月info | 年同比变化 |
---|---|---|
现金及短期投资 | 5.12亿 | -23.74% |
总资产 | 17.05亿 | -20.42% |
负债总额 | 20.40亿 | -3.37% |
权益总额 | -3.35亿 | — |
发行在外的股份 | 3766.27万 | — |
市净率 | -8.24 | — |
资产回报率 | -6.44% | — |
资本回报率 | -7.90% | — |
现金流
现金净变动
(EUR) | 2024年6月info | 年同比变化 |
---|---|---|
净收入 | -7919.31万 | -7.07% |
来自运营的现金 | -1.31亿 | -4.25% |
投资现金 | 1.17亿 | 402.25% |
融资现金 | -298.13万 | 36.22% |
现金净变动 | 241.34万 | 102.25% |
自由现金流 | 3.95亿 | 464.18% |
简介
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG was listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
CEO
成立时间
1992
总部
员工数量
446